sanofi-aventis U.S. LLC drugs

6 results

Ambien (zolpidem tartrate)

(zolpidem tartrate)
sanofi-aventis U.S. LLC
Usage: AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep initiation, and has been shown to reduce sleep latency for up to 35 days in clinical studies.

Ambien (zolpidem tartrate)

(zolpidem tartrate)
sanofi-aventis U.S. LLC
Usage: AMBIEN CR (zolpidem tartrate extended-release tablets) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep onset and/or maintenance, as assessed by wake time after sleep onset. Clinical trials support its efficacy for up to 24 weeks in adults.

Ferrlecit (sodium ferric gluconate complex)

(sodium ferric gluconate complex)
sanofi-aventis U.S. LLC
Usage: Ferrlecit is indicated for treating iron deficiency anemia in adults and pediatric patients aged 6 and older with chronic kidney disease on hemodialysis who are receiving supplemental epoetin therapy.
sanofi-aventis U.S. LLC
Usage: Mozobil, in combination with filgrastim, is indicated for mobilizing hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.

Soliqua 100/33 (insulin glargine and lixisenatide)

(insulin glargine and lixisenatide)
sanofi-aventis U.S. LLC
Usage: SOLIQUA 100/33, combining insulin glargine and lixisenatide, is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with a history of pancreatitis, type 1 diabetes, diabetic ketoacidosis, or gastroparesis.

Zaltrap (ziv-aflibercept)

(ziv-aflibercept)
sanofi-aventis U.S. LLC
Usage: ZALTRAP is indicated for the treatment of metastatic colorectal cancer (mCRC) in patients who have either developed resistance to or progressed after receiving an oxaliplatin-containing regimen, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI).